ArticleFrontiers in immunology2021
ASCVac-1, a Multi-Peptide Chimeric Vaccine, Protects Mice Against
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Current Efficacy of Multiepitope Vaccines Against Helminths: A Systematic Review.Biomolecules · 2025Pooled it
- Design of a Multi-Epitope Vaccine Based onInternational journal of molecular sciences · 2025Article
- Repeat Ascaris challenge reduces worm intensity through gastric cellular reprograming.PLoS neglected tropical diseases · 2025Article
- Development of multi-epitope Cathepsin L driven short peptide vaccine againstFrontiers in veterinary science · 2025Article
- Ascaris Mouse Model Protocols: Advancing Research on Larval Ascariasis Biology.Current protocols · 2024Article
- Enhanced protective immunity against Baylisascaris schroederi infection in mice through a multi-antigen cocktail vaccine approach.Parasitology research · 2023Article
- Evaluation of the immunoprotective effects of eight recombinant proteins from Baylisascaris schroederi in mice model.Parasites & vectors · 2023Article
- In silico design of a polypeptide as a vaccine candidate against ascariasis.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Control of human ascariasis, the most prevalent neglected tropical disease globally affecting 450 million people, mostly relies on mass drug administration of anthelmintics. However, chemotherapy alone is not efficient due to the high re-infection rate for people who live in the endemic area. The development of a vaccine that reduces the intensity of infection and maintains lower morbidity should be the primary target for infection control. Previously, our group demonstrated that immunization with crude
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.